We obtained blood samples from individuals with PTB and LTBI that attended the TB clinic of the Instituto Nacional de Enfermedades Respiratorias “Ismael Cosío Villegas” (INER), in Mexico City. The PTB group included patients with positive results in sputum smear microscopy, sputum/BAL culture, and GeneXpert
MTB/RIF test (Cepheid, CA, USA), according to the ATS/IDSA/CDC guidelines (n=25). LTBI in healthy close-contacts of PTB patients was confirmed by positive results in
QuantiFERON®-TB Gold Plus (QFT®-Plus) test (QIAGEN, Hilden, Germany) (n=17).
For histological studies, lung sections were obtained from participants with PTB from the Tuberculosis Outpatient Clinic at the National Institute of Respiratory Diseases (INER) in Mexico City. Samples were obtained from participants before anti-
Mtb treatment.
All participants or their legal guardians provided written informed consent to participate in the study. Blood samples were processed and stored according to the Mexican Constitution law NOM-012-SSA3-2012, which establishes criteria for the execution of clinical research projects in humans. The current study was reviewed and approved by the Institutional Review Board of the INER (project number B04-15). Information about the donor’s sex, age, and TB infection status is listed in
Supplementary Table S3.
Esaulova E., Das S., Singh D.K., Choreño-Parra J.A., Swain A., Arthur L., Rangel-Moreno J., Ahmed M., Singh B., Gupta A., Fernández-López L.A., Garcia-Hernandez M.D., Bucsan A., Moodley C., Mehra S., García-Latorre E., Zuniga J., Atkinson J., Kaushal D., Artyomov M.N, & Khader S.A. (2020). The immune landscape in tuberculosis reveals populations linked to disease and latency. Cell host & microbe, 29(2), 165-178.e8.